Transgene SA Asset Resilience Ratio
Transgene SA asset resilience ratio. Transgene SA (TNG) has an Asset Resilience Ratio of 75.78% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See TNG cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Transgene SA (2011–2025)
Asset resilience ratio of Transgene SA from 2011 to 2025. This chart shows how Transgene SA's Asset Resilience Ratio has changed over time. Read Transgene SA balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Transgene SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see TNG asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €105.20 Million | 75.78% |
| Total Liquid Assets | €105.20 Million | 75.78% |
Asset Resilience Insights
- Very High Liquidity: Transgene SA maintains exceptional liquid asset reserves at 75.78% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Transgene SA Industry Peers by Asset Resilience Ratio
Compare Transgene SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Transgene SA Asset Resilience Ratio by Year (2011–2025)
Transgene SA asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for Transgene SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 75.78% | €105.20 Million ≈ $122.99 Million |
€138.83 Million ≈ $162.30 Million |
+42.03pp |
| 2022-12-31 | 33.75% | €22.42 Million ≈ $26.21 Million |
€66.44 Million ≈ $77.67 Million |
-9.12pp |
| 2021-12-31 | 42.87% | €43.66 Million ≈ $51.04 Million |
€101.84 Million ≈ $119.06 Million |
+18.21pp |
| 2020-12-31 | 24.67% | €21.08 Million ≈ $24.64 Million |
€85.45 Million ≈ $99.90 Million |
-11.73pp |
| 2019-12-31 | 36.40% | €42.03 Million ≈ $49.14 Million |
€115.48 Million ≈ $135.00 Million |
+22.56pp |
| 2018-12-31 | 13.83% | €15.02 Million ≈ $17.55 Million |
€108.54 Million ≈ $126.90 Million |
-25.58pp |
| 2017-12-31 | 39.42% | €39.76 Million ≈ $46.49 Million |
€100.87 Million ≈ $117.93 Million |
-2.35pp |
| 2016-12-31 | 41.77% | €51.35 Million ≈ $60.04 Million |
€122.95 Million ≈ $143.74 Million |
+13.65pp |
| 2015-12-31 | 28.12% | €28.36 Million ≈ $33.16 Million |
€100.87 Million ≈ $117.93 Million |
-16.17pp |
| 2014-12-31 | 44.29% | €62.42 Million ≈ $72.98 Million |
€140.95 Million ≈ $164.79 Million |
+10.34pp |
| 2013-12-31 | 33.95% | €42.72 Million ≈ $49.95 Million |
€125.85 Million ≈ $147.13 Million |
-20.13pp |
| 2012-12-31 | 54.08% | €86.78 Million ≈ $101.45 Million |
€160.46 Million ≈ $187.60 Million |
-17.09pp |
| 2011-12-31 | 71.17% | €137.77 Million ≈ $161.07 Million |
€193.58 Million ≈ $226.32 Million |
-- |
About Transgene SA
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) posi… Read more